GENE ONLINE|News &
Opinion
Blog

2020-01-24| R&D

Polivy – A New and Improved Arsenal from Roche to Fight DLBCL Relapse

by Sahana Shankar
Share To

By Sahana Shankar

In another step towards fighting relapsed Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer, Roche scores EU approval for its novel combination therapy.

Roche announces that its antibody-drug conjugate, Polivy (polatuzumab vedotin) has received conditional marketing authorization from the European Commission, benefiting relapse patients. In June 2019, the US FDA had given accelerated approval for Polivy, to be used as a combination therapy with bendamustine and Rituxan (BR), for patients with relapsed DLBCL who have undergone 2 rounds of therapy.

Polivy was designated as Breakthrough Therapy by FDA and PRIME (PRIority MEdicines) by the European Medicines Agency (EMA) in 2017 to expedite its development and clinical trials to provide preliminary evidence and improve current therapies substantially. With approvals for its conditional use in the US and EU, Roche continues to investigate Polivy’s efficacy in Non-Hodgkin’s Lymphoma (NHL).

Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is an aggressive Non-Hodgkin’s Lymphoma that affects B- lymphocytes, the blood cells which produce antibodies to protect against infections. The GLOBOCAN survey estimates 18,000 annual cases in the US and around 150,000 people are affected worldwide every year, making it the most prevalent NHL. It initiates in the lymph nodes but could spread to any organ. With the current combination regimen, DLBCL is considered potentially curable, despite its aggressiveness. However, reports indicate that the first 24 month period in remission is crucial and up to 40% of patients relapse with a more robust malignancy and limited survival, partly due to limited treatment options.

Clinical Trial Evaluation

The combination therapy of Polivy with BR benefits adults with relapsed DLBCL who are not suitable candidates for a stem cell transplant. Polivy’s claim to fame comes from a global, phase Ib/II clinical study that evaluated its safety, tolerability, and activity. A randomized trial with 80 relapsed patients resulted in:

  • A complete response (no detectable cancer at the time of assessment) in 40% of people treated as opposed to 17.5% with BR treatment only
  • Patients treated with Polivy + BR had better survival with a median of 12.4 months versus 4.7 months with BR only
  • Polivy + BR resulted in a longer time (10.3 months) between first response to treatment and deterioration as compared to BR treatment (4.1 months)

Polivy performed better than BR treatment across the board with better progression-free survival, event-free survival, and overall survival.

Polivy – Mode of Action

CD79 is an antigen receptor complex associated protein. Polivy acts by recognizing the B-cell specific membrane marker CD79b and selectively eliminates B-cells by delivering an anti-cancer agent. This minimizes damage to healthy cells and improves efficacy, making Polivy a first-in-class anti-CD79b antibody-drug conjugate.

This brings Roche’s count of approved drugs for hematologic diseases to 5 and their investigation pipeline includes candidates to broaden the portfolio and offer combinatory solutions to most blood disorders.

References

  1. https://www.roche.com/media/releases/med-cor-2020-01-21.htm
  2. https://lymphoma.org/aboutlymphoma/nhl/dlbcl/
  3. https://www.roche.com/media/releases/med-cor-2019-06-11b.htm

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
Roche’s Gantenerumab Fails Trials In Alzheimer’s Disease
2022-11-15
Roche Clocks Clinical Win as it Eyes Additional Vabysmo Indication
2022-10-27
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!